Teva nabs experimental Tourette drug in $700M Emalex buyout

FierceBiotechFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death

Endpoints NewsAbbVie faces questions about Skyrizi competition from J&J

Endpoints NewsFDA, AstraZeneca prep for oncology adcomm

AgilentPCR Plate Sealer Market Leading Players Analysis - Agilent - openPR.com

Thermo FisherLeading biotech company launches its first US drug processing hub in Mass. - MassLive

10x Genomics NewsWhy 10x Genomics Stock Is Sinking Today - TipRanks

Lonza NewsLonza Capsugel donates $50,000 to Project Hope Foundation - Index-Journal

FierceBiotechAstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial

FierceBiotechRising costs push GE HealthCare to cut outlook as it restructures units and leadership

FierceBiotechTeva inks $700M Emalex buyout to bag near-approval Tourette drug

FierceBiotechAstraZeneca restarts £300M investment in UK, but Merck not budging

CellSpatial organization and detection of social odors in mouse primary olfactory system